CARMA™ News & More

CARMA™ News

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program
16 July 2018
Read Full Release »
 
MaxCyte, Inc. to Present at 2018 BIO International Convention
May 29, 2018
Read Full Release »
 
MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer
April 25, 2018
Read Full Release »
 
MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month
March 12, 2018
Read Full Release »
 
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
March 2, 2017
Read Full Release »
 
MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies
December 21, 2016
Read Full Release »
 
MaxCyte Appoints Executive Vice President, Business and Strategic Development
November 2, 2016
Read Full Release »
 
MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies
April 21, 2015
Read Full Release »

CARMA Scientific Publications

Development of anti-human mesothelin-targeted chimeric antigen receptor (CAR) messenger RNA (mRNA)-transfected peripheral blood lymphocytes (CARMA-hMeso) for ovarian cancer therapy
Human Gene Therapy
2018 Jan 15. doi: 10.1089/hum.2017.080
 
2017 AACR Annual Meeting Abstract: Development of anti-human mesothelin chimeric antigen receptor (CAR) messenger RNA (mRNA) transfected peripheral blood mononuclear cells (CARMA) for the treatment of mesothelin-expressing cancers

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Request Demo